Market News AIOpen the app

Nasus Pharma Presents Positive Phase 2 Data for Intranasal Epinephrine Candidate NS002

TrialRead the original at globenewswire.com
Good for NSRX

Nasus Pharma said NS002 reached treatment levels faster than autoinjectors, including with severe nasal congestion, and no serious medical problems were reported. This supports its promise, but the pivotal study and its results still lie ahead.

NSRX · Nasus Pharma

AI read · Good for NSRX

The AI's read

That gives NS002 early evidence that it may work when nasal congestion is severe and when doses are repeated. No serious medical problems were reported. The study was still an early test, and the pivotal study has not begun. Its results are expected in the first quarter of 2027.

Get alerts for NSRX

Follow Nasus Pharma (NSRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NSRX
Free on the App Store and Google Play, or on the web.